Wright Casey W, Duckett Colin S
Department of Pathology, and Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA.
J Clin Invest. 2005 Oct;115(10):2673-8. doi: 10.1172/JCI26251.
Recent studies have shown that members of the inhibitor of apoptosis (IAP) protein family are highly expressed in several classes of cancer. The primary implication of these findings is that the elevated expression of IAPs is not coincidental but actually participates in oncogenesis by helping to allow the malignant cell to avoid apoptotic cell death. This concept, together with the discovery of several IAP-regulatory proteins that use a conserved mode of action, has stimulated a major effort by many research groups to devise IAP-targeting strategies as a means of developing novel antineoplastic drugs. In this Review, we consider the evidence both for and against the IAPs being valid therapeutic targets, and we describe the types of strategies being used to neutralize their functions.
最近的研究表明，凋亡抑制蛋白（IAP）家族成员在几类癌症中高度表达。这些发现的主要意义在于，IAPs的高表达并非偶然，而是实际上通过帮助恶性细胞避免凋亡性细胞死亡而参与肿瘤发生。这一概念，连同发现的几种采用保守作用模式的IAP调节蛋白，促使许多研究小组做出重大努力，设计针对IAP的策略作为开发新型抗肿瘤药物的一种手段。在本综述中，我们考虑了支持和反对IAPs作为有效治疗靶点的证据，并描述了用于中和其功能的策略类型。
